This study investigates the combined use of CDK4/6 inhibition with Palbociclib and anti-VEGF targeting with Bevacizumab in solid tumors. It enrolls patients over 18 with stage III/IV disease in selected cancer types such as colorectal, lung, genitourinary, or breast cancer. The study is being conducted in Phase 1 and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Individuals of white ethnicity. * Age between \> 18 * Both males and females. * Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer). * Cancer stage III/ IV with or without metastasis or lymph node dissemination at the time of enrollment. * Unrelated patients. Exclusion Criteria: * History of hematological cancer types or previous cancers, recurrent or relapse. * Diagnosis of inflammatory bowel diseases. * Pre-existing cardiovascular diseases or coronary artery diseases. * Confirmed treated or untreated autoimmune diseases. * Metabolic disorders, diabetes, or hypertension. * Neurological diseases. * Evidence of cardiac, renal, bone, or cerebral damage. * Presence of more than one type of malignancies. * Active infections or myositis. * Familial polyposis. * Alcohol or smoking habits. * Body mass index (BMI) \>30. * Significant weight loss within the last 2 years. * History of surgeries. * Pregnancy. * Related patients.